Clinical trials
Adenocarcinoma of Esophagogastric Junction clinical trials
Below are recruiting adenocarcinoma of esophagogastric junction clinical trials, each written for real people, not researchers. We’re tracking 29 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05177133RecruitingPhase 2
First-line treatment for MSI-high stomach or esophagus cancer
This Phase 2 trial tests whether adding an anti–PD-1 immunotherapy (retifanlimab) and chemotherapy (capecitabine plus oxaliplatin, with leucovorin) works better for people with metastatic or inoperable stomach or gastroesophageal junction cancer that has defective mismatch repair (dMMR). If you’re eligible, it may help shrink tumors and slow the disease without needing prior chemotherapy for metastatic cancer.
AmsterdamAges 18 years+ - NCT04443478Recruiting
Keyhole versus open lymph node surgery for junction cancer
This trial compares two ways of removing lymph nodes during surgery: keyhole (laparoscopic) versus open surgery. It is for people with esophagus-stomach junction adenocarcinoma, aiming to see which approach works better and is safer.
Beijing, Beijing MunicipalityAges 18–80 - NCT04455282Recruiting
Blood test-guided surgery for gastroesophageal cancer
This trial studies blood-based biomarkers to help doctors choose the best individualized surgical treatment for gastroesophageal junction adenocarcinoma. If you qualify, you’ll get standard care plus additional testing to see whether the blood results can guide surgery more precisely.
Cologne, North Rhine-WestphaliaAges 18 years+ - NCT06158919Recruiting
Immunotherapy Plus Targeted Therapy and Chemo for Stomach Cancer
This trial tests a combination of immunotherapy (PD-1 inhibitor), a targeted drug (fruquintinib), and chemotherapy as a first treatment for advanced stomach or gastroesophageal junction cancer that is HER2-negative. It aims to see if this combination can shrink tumors and help people live longer.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT06766305RecruitingPhase 1/Phase 2
QL1706 combined with SOX before and after stomach cancer surgery
This trial tests a new combination of drugs (QL1706 plus chemotherapy SOX) given before and after surgery for stomach or gastroesophageal junction cancer. It aims to shrink the tumor before surgery and help prevent recurrence afterward.
Hangzhou, ZhejiangAges 18–75
Hear when a new Adenocarcinoma of Esophagogastric Junction trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for adenocarcinoma of esophagogastric junction?
- Yes. Clin2 currently lists 29 recruiting adenocarcinoma of esophagogastric junction studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a adenocarcinoma of esophagogastric junction trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a adenocarcinoma of esophagogastric junction trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Gastric or Esophagogastric Junction Adenocarcinoma
- Siewert Type II Adenocarcinoma of Esophagogastric Junction
- Gastroesophageal Junction Adenocarcinoma
- Gastric / Gastroesophageal Junction Adenocarcinoma
- Metastatic Gastroesophageal Junction Adenocarcinoma
- Gastroesophageal Junction (GEJ) Adenocarcinoma
- Advanced Gastroesophageal Junction Adenocarcinoma
- Gastric or Gastroesophageal Junction Adenocarcinoma
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.